FDA Commissioner Califf's Pharmaceutical Industry Revolving Door Scrutinized

confirmed Importance 8/10 ~1 min read 3 sources 5 actors

FDA Commissioner Robert Califf faces ongoing criticism for his extensive pharmaceutical industry ties. Having received over $8 million from drug companies and worked as a consultant for major pharmaceutical firms, Califf pledged to extend post-employment restrictions from 2 to 4 years to mitigate ‘revolving door’ concerns. His connections include consulting roles with Merck, Biogen, Eli Lilly, and a leadership position at Verily Life Sciences (Alphabet).

Sources & Citations

[1] Califf Pledges Not to Use Revolving Door Between FDA and Industry Tier 2

[2] Will Biden's FDA Be Led by a Pharma Guy? Tier 2

[3] Manchin Criticizes Califf's FDA Nomination Over Industry Ties · Sep 20, 2024 Tier 1

Tiers Tier 1 court records & gov docs · Tier 2 established outlets · Tier 3 regional & specialty press · Tier 4 opinion or single-source. Methodology →

Cite this entry

The Cascade Ledger. “FDA Commissioner Califf's Pharmaceutical Industry Revolving Door Scrutinized.” The Capture Cascade Timeline, September 20, 2024. https://capturecascade.org/event/2024-09-20--fda-commissioner-robert-califf-revolving-door-patter/